# Fredun Pharmaceuticals share price today (Fredun Pharmaceuticals Ltd, NSE: FREDUN)

> Fredun Pharmaceuticals share price today: ₹1,454.50 at the NSE close on 3 November 2026, up 183.5% in a year. Fredun Pharmaceuticals (NSE: FREDUN) is worth ₹2,491 crore, trades at a P/E of 56.1 and has closed between ₹479.02 and ₹1,553.15 over the past 52 weeks. > Fredun Pharmaceuticals Ltd's share price has risen faster than its earnings: +183.5% in a year, against +38.2% for earnings per share. FREDUN · Pharma - Formulators · data as of 3 November 2026. Page: https://www.sectoralpha.in/stocks/fredun-pharmaceuticals-ltd

Sector Alpha also publishes a daily newsletter that explains one Indian stock at a time: https://newsletter.sectoralpha.in/?utm_source=sectoralpha&utm_medium=ai_text&utm_campaign=llms

## Key numbers

- Business trend: Getting better, from the last 12 quarters
- Price: ₹1,454.50 (+183.5% in a year)
- P/E: 56.1× (higher than 78% of the last 11 years)
- Revenue (Jun 2026): ₹228 Cr (+90.0% on a year ago)
- Profit (Jun 2026): ₹13.0 Cr (+85.7% on a year ago)
- Operating margin: 14.0% (flat on a year ago)
- ROCE: 21%, FY26
- ROIC: 14.1%, against a 12.0% cost of capital: +2.1 points

The main question: profits are rising, but only −7% of the last 3 years' profit came in as cash from operations. The gap between reported profit and actual cash is the thing to watch. ## What is the Fredun Pharmaceuticals share price today? Fredun Pharmaceuticals Ltd's share price was ₹1,454.50 at the close on 3 November 2026. It has been rising for 70 weeks. That is 43.9% above its average price over the last 200 trading days. In the last 52 weeks it traded between ₹479 and ₹1,553, and at that close it sat 91% of the way up from that low. Over the past 13 weeks it has done better than the NIFTY 500, and it has stayed ahead for 20 weeks in a row. Over the last 11 years the share price moved +34,780% while the NIFTY 500 moved +243%, so it is ahead of the index over that whole period. The chart above shows the 13-week comparison for every week. This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row. ## What changed at Fredun Pharmaceuticals this quarter? Three changes stood out: revenue up on a year earlier for 11 quarters in a row (every quarter we can compare), profit up on a year earlier for 7 quarters in a row and highest quarterly profit in 15 quarters. 1. Revenue up on a year earlier for 11 quarters in a row (every quarter we can compare) In the June 2026 quarter revenue was ₹228 crore, +90% on a year earlier. Why: Revenue rose because the company had stocked ingredients earlier, protected customer prices and got extra orders. From the earnings call on 13 Aug 2026. 2. Profit up on a year earlier for 7 quarters in a row In the June 2026 quarter profit was ₹13 crore, +85.7% on a year earlier. Why: Profit rose because more of the sales came from higher margin newer products and better registrations in older markets. Next results: check whether the share of sales left as profit rises from selling more higher margin products and repeat orders, not from giving up profit. From the earnings call on 13 Aug 2026. 3. Highest quarterly profit in 15 quarters Profit of ₹13 crore in the June 2026 quarter is the highest of the last 15 quarters. Why: The record profit came from the same shift to higher margin newer products, better registrations in older markets and deeper customer reach. Next results: check whether the share of sales left as profit keeps improving as newer products sell more. From the earnings call on 13 Aug 2026. ## What are Fredun Pharmaceuticals' latest quarterly results? For April to June 2026 (the quarter ended 30 June 2026), Fredun Pharmaceuticals reported revenue of ₹228 crore, up 90.0% from ₹120 crore a year earlier, and a profit of ₹13.0 crore, up 85.7% from ₹7.00 crore. ### Fredun Pharmaceuticals results: April to June 2026 against a year earlier

| Measure | April to June 2026 | April to June 2025 | Change |
| --- | --- | --- | --- |
| Revenue | ₹228 crore | ₹120 crore | +90.0% |
| Profit | ₹13.0 crore | ₹7.00 crore | +85.7% |
| Earnings per share | ₹7.98 | ₹4.77 | +67.3% |
| Operating margin | 14.0% | 14.0% | 0.0 points |

The next results, for July to September 2026, are due by 14 November 2026: listed companies must publish quarterly results within 45 days of the quarter's end (60 days for the January to March quarter). Fredun Pharmaceuticals' management discussed these results on a call held on 13 August 2026; what it said is further down this page. (From the company's reported quarterly results (quarter ended 30 June 2026). Revenue and profit in ₹ crore.)

## What is the Fredun Pharmaceuticals share price history? Fredun Pharmaceuticals closed at ₹1,454.50 on 3 November 2026, up 183.5% from ₹513.05 a year earlier (31 October 2025) and up 761.7% over five years. Its highest weekly close since March 2016 was ₹1,553.15 on 9 October 2026. ### Fredun Pharmaceuticals share price: then and now

| When | Close | Change to 3 Nov 2026 |
| --- | --- | --- |
| 1 week ago · 23 Oct 2026 | ₹1,368.10 | +6.3% |
| 1 month ago · 1 Oct 2026 | ₹1,353.00 | +7.5% |
| 1 year ago · 31 Oct 2025 | ₹513.05 | +183.5% |
| 3 years ago · 3 Nov 2023 | ₹273.90 | +431.0% |
| 5 years ago · 4 Nov 2021 | ₹168.80 | +761.7% |
| 10 years ago · 4 Nov 2016 | ₹13.00 | +11,088.5% |
| Earliest and lowest weekly close in our records · 28 Mar 2016 | ₹4.17 | +34,780.1% |
| Highest weekly close since March 2016, also the 52-week high · 9 Oct 2026 | ₹1,553.15 | −6.4% |
| 52-week low (weekly close) · 9 Jan 2026 | ₹479.02 | +203.6% |

Weekly closing prices, adjusted for splits and bonuses so every price is on today’s share count. Each change is the move from that price to the 3 Nov 2026 close. A day's intraday high or low can go beyond these weekly closes. (492 weekly closes from 28 March 2016 to 3 November 2026.)

## What is the latest news on Fredun Pharmaceuticals? 3 Nov 2026: Fredun Pharmaceuticals closed at ₹1,454.50, up 6.3% on the week and up 7.5% on the month. 13 Aug 2026: Fredun Pharmaceuticals held its results call for April to June 2026. Management guided: New-age brands 35-45% annually and vintage business 15-20%; blended company growth 35-40% over 3 years; Fredun GX 25-35% over 5 years, or 30-35% over 4 years. ### Earlier

- Results for April to June 2026: Revenue up 90.0% and profit up 85.7% on a year earlier. ## What dividend does Fredun Pharmaceuticals pay? The NSE corporate-actions record has no dividend for Fredun Pharmaceuticals since 1 April 2021, so this page cannot show amounts per share. Yes. Fredun Pharmaceuticals Ltd paid out 1% of its profit as dividends in FY26, and it paid a dividend in 11 of its last 13 reported years. (From the NSE corporate-actions record, read 4 November 2026.)

## What did Fredun Pharmaceuticals management say on the latest results call? On the call for April to June 2026, held on 13 August 2026, Fredun Pharmaceuticals' management guided: New-age brands 35-45% annually and vintage business 15-20%; blended company growth 35-40% over 3 years; Fredun GX 25-35% over 5 years, or 30-35% over 4 years. > “A blended growth of somewhere around 35-40% for the next 3 years is on the charts.”
> Fredun Medhora, MD, on the call for April to June 2026

### What management guided

- FY27 revenue goal around ₹800 crore; coming quarters and next year expected to sustain a similar growth pace. - Pet-care growth 40-50% annually over 3-4 years; cat-food launch expected Q3/January to March 2027 and its business planned at ₹100 crore within 3-3.5 years of launch. - Wagr brand onboarding within 20-25 days, beta work within 60-65 days and major campaigns within 90 days. - Capital spending ₹30-40 crore in FY27 and similar next year, broader two-year framing ₹35-45 crore annually; supports a top-tier single-location unit by end-December 2028 or early 2029. Management’s own plans and goals, from our notes of the call. A plan is not a result. Source: [the call transcript](https://files.tijorifinance.com/insight/india/6251/Conference Call/CC-Aug26.pdf). (From the call for April to June 2026, 13 August 2026.)

## What to watch in Fredun Pharmaceuticals' next results? When Fredun Pharmaceuticals reports July to September 2026, these are the 4 checks that show whether the story is still on course. First: Revenue trajectory versus the stated annual goal - check whether growth stays near Q1 pace after prior-quarter stocking benefits normalize. - What to check (from the call)
- Revenue trajectory versus the stated annual goal - check whether growth stays near Q1 pace after prior-quarter stocking benefits normalize. - Operating margin progression with new-age mix - check whether expansion follows penetration and repeat-order gains rather than margin sacrifice. - Inventory and cash conversion - check movement toward management's normalization band as SKU breadth and launches expand. - Own-facility expansion and capital spending deployment - check functional-food capacity progress and movement toward the larger single-location footprint. ## Which stock lists is Fredun Pharmaceuticals on? Fredun Pharmaceuticals is on 2 of our India lists: Momentum stocks and Pharma stocks. - [Momentum stocks Market cap cr: 2411.5553767373813](https://www.sectoralpha.in/momentum-stocks-india)
- [Pharma stocks Market value (₹ crore): 2411.5553767373813](https://www.sectoralpha.in/sectors/pharma-stocks-india)

## Is Fredun Pharmaceuticals profitable? Fredun Pharmaceuticals Ltd earned ₹13.0 Cr of net profit in the Jun 2026 quarter, +85.7% on the same quarter a year earlier. That is the 7th quarter in a row of profit growth. Full-year FY26 profit was ₹33.0 Cr. Over 10 years profit has grown 41.9% a year on average. That is 5.7% of the quarter's revenue. The same quarter a year earlier earned ₹7.0 Cr. For the full year, FY26 profit was ₹33.0 Cr (+57.1% on the year before). Why profit moved: revenue changed +90.0% on a year earlier and the margin moved +0.0 percentage points. Sales did the work, and the margin was about flat. On average over the last four quarters, profit changed +98.2% and revenue +52.3%. Profit is growing faster than sales: fixed costs are spread over more sales, so each extra rupee of revenue adds more to profit. ## How much revenue does Fredun Pharmaceuticals make, and is it growing? Fredun Pharmaceuticals Ltd reported ₹228 Cr of revenue in the Jun 2026 quarter, +90.0% on the same quarter a year earlier. That is the 12th quarter in a row with growth on the year before. Over 10 years it has grown 31.2% a year on average. The last full year, FY26, came in at ₹635 Cr. The last four reported quarters add to ₹747 Cr. FY26 revenue was ₹635 Cr, +39.9% on the year before. Recent pace: the last four quarters grew +52.3% on average, against 31.2% a year over the longer run, so this year is growing faster than its own long-run rate. Is growth speeding up? Revenue over the last 12 months grew +50.3%, against +42.9% a year over the last 8 quarters (accelerating); profit over the last 12 months grew +91.3%, against +60.9% a year (accelerating). ## How much of every ₹100 of sales does Fredun Pharmaceuticals keep? Fredun Pharmaceuticals Ltd's operating margin was 14.0% in the Jun 2026 quarter, about the same as the same quarter a year ago. Its latest full-year margin is the highest it has ever reported. Across 13 years it has been between 6.0% and 14.0%. The latest quarter is within that range. In the latest quarter it moved +0.0 percentage points on the same quarter a year ago. Why the margin moved: operating margin changed +0.2 percentage points on the year while gross margin changed −5.5 points. So the gain came mostly from the gross margin, which means input costs and prices charged. When margins are at a record, every ratio built on profit looks better than usual, so watch whether they hold. ## Is Fredun Pharmaceuticals' profit turning into cash? Over the last 3 years Fredun Pharmaceuticals Ltd's operations used more cash than they brought in, so cash conversion was −7%, a gap worth watching. In FY26 it brought in ₹16.0 Cr of operating cash against ₹33.0 Cr of profit. After ₹73.0 Cr of spending on assets, free cash was −₹57.0 Cr: it spent more than its operations brought in. Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year. Why −7% of profit came in as cash: the cash cycle got 62 days longer between FY21 and FY26, so more of each rupee of profit waits in the business before it arrives. When less than 70% of profit comes in as cash, it is the thing to watch on this page. What to look at next: less of the profit turns into cash than it should, and the cash cycle is 62 days longer. The next section looks at where the cash is stuck. ## Where does Fredun Pharmaceuticals' cash go? Fredun Pharmaceuticals Ltd's cash cycle, the days between paying suppliers and getting paid by customers, was 201 days in FY26, up from 139 days in FY21. It spent ₹95.0 Cr on assets over the last 3 years. Customers take 53 days to pay, and stock sits for 219 days on average. At FY26 sales of ₹635 Cr, each day of that cycle ties up about ₹1.7 Cr, so roughly ₹350 Cr is tied up in the business at any time. FY26: customers took 53 days to pay and stock sat for 219 days, about 7.2 months of sales sitting as stock, for a full cycle of 201 days, longer than FY21's 139. The full loop: cash goes out to suppliers and production on day 0. Stock sits for 219 days. Customers pay about 53 days after that. Suppliers are paid at 71 days. Together that makes the 201-day cycle. Spending on assets: ₹95.0 Cr over the last 3 years, against ₹16.0 Cr of depreciation (the yearly wear and tear on existing assets). So it is building well beyond replacing what wears out. Work still in progress is ₹0.0 Cr (FY26): assets paid for that are not earning yet. In short: cash is getting stuck in the daily cycle, so watch the cycle more than the profit. ## What is Fredun Pharmaceuticals' P/E ratio, and how does it compare with its own history? Fredun Pharmaceuticals Ltd's P/E is 56.1×, near the high end of its own history: higher than 78% of past readings. Its usual P/E (the middle reading) is 33.3×, over 11 years of weekly prices. This compares the share price with the company’s own past. It does not say what the business is worth. The P/E here, and its history, use a profit figure that can leave out one-off items, so it can differ from a P/E worked out on the quarterly results. Those results' earnings per share for the four quarters to Jun 2026 add up to ₹28.09. Why the multiple is where it is: over the past year earnings per share moved +38.2% while the price moved +183.5%. The price did better than earnings, which pushed the multiple up within its own range. Where the price move came from: over 5 years the price moved +53.8% a year; about +48.0% a year came from earnings growth and about +5.8 percentage points from the multiple (the market paying more); over 10 years the price moved +60.3% a year; about +27.3% a year came from earnings growth and about +33.0 percentage points from the multiple (the market paying more). The split is approximate (price return minus earnings growth). It shows how much of the move came from the market paying a different multiple. In short: the multiple is high against its own past, so the earnings trend underneath matters more than the multiple. ## Is the Fredun Pharmaceuticals business getting better or worse? Fredun Pharmaceuticals Ltd's business is getting better. EPS growth hit its low 8 quarters ago at −39.8% and has recovered to +70.1%, with ROCE rising at 40.5%. This is based on 12 quarters of 4 measures. Why it matters: a lasting rise from a low is what this page is built to show. ## How much does Fredun Pharmaceuticals earn on its capital? Fredun Pharmaceuticals Ltd earned a ROCE of 21% in FY26. That is up from a low of 10% in FY20. Its return on capital used (ROIC) is 2.1 percentage points above its cost of capital, so growth here adds value, not just size. It comes from a 5.2% net margin and 0.99× asset turnover (sales divided by assets). Why the return is what it is (FY26): a 5.2% net margin × 0.99× asset turnover × 2.31× leverage (assets divided by equity) ≈ 11.9% on equity. The margin does its share; borrowing is a big part of it. The key test, return on capital used minus the cost of capital: 14.1% − 12.0% = +2.1 percentage points. The 12.0% is a standard assumption for the cost of capital in India, not an estimate for this company. Read the sign and size of the gap, not the decimals. Positive but thin: it creates value with little room for error. The 14.1% ROIC above is the latest reading, as reported. The yearly chart below shows FY26 at 15.1%, and the quarterly chart works out each 12-month window from the quarterly figures, so the readings differ by date, not by method. ## Does Fredun Pharmaceuticals have too much debt? Fredun Pharmaceuticals Ltd has total debt of ₹242 Cr against shareholder equity of ₹278 Cr as of Jun 2026, so its debt is 0.87× its equity. Year by year, that ratio went from 0.90 in FY22 to 0.87 in FY26. Keep that borrowing in mind when reading the returns on this page. ## What is the Fredun Pharmaceuticals shareholding pattern? Promoters cut their stake in Fredun Pharmaceuticals Ltd by 5.3 percentage points over 8 quarters, the biggest change among its owners. Promoters now own 43.6% of the company. Domestic institutions moved +1.8 points over the same period, to 3.4%. This uses the four owner groups that companies report every quarter; nothing is guessed between filings. Over the last two years: Promoters: −5.3 points over 8 quarters, to 43.6%; Domestic institutions: +1.8 points over 8 quarters, to 3.4%; Foreign institutions: +0.7 points over 8 quarters, to 0.7%. Why the owners changed: promoters drove it (−5.3 points), with the other side taken by domestic institutions (+1.8 points). They reduced their stake. ## How far is Fredun Pharmaceuticals from balance-sheet trouble? For Fredun Pharmaceuticals Ltd, the Z-score is not available, so we say so rather than guess one. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. The debt, cash-flow and return sections show the balance-sheet figures we do have, each with its own date. ## How does Fredun Pharmaceuticals rank in its industry? 65.8 out of 100, rank 7 of 44 in Pharma - Formulators, with 76% of the evidence available. Fredun Pharmaceuticals Ltd scores 65.8 out of 100 against the 44 companies it is compared with in Pharma - Formulators, ranking 7. There is no relative-strength reading for this week, so the score is built from earnings, capital efficiency and valuation alone. The three scored parts add up to the total exactly: 31.9 + 19 + 14.9 = 65.8 (no relative-strength reading this week; its 20 points are shared across the other three). This is the same number shown on the industry page; it is worked out once for the whole group and read here. What would change it: The score would fall if profit growth turns negative or margins stop improving while the share price lags its sector. ## Which companies is Fredun Pharmaceuticals compared with? Fredun Pharmaceuticals ranks 7 of 44 Pharma - Formulators companies on the 4-Factor Sector Score, with 65.8 out of 100. 1. [Rubicon Research Ltd](https://www.sectoralpha.in/stocks/rubicon-research-ltd) RUBICON · leader · Most evidence points up · 83% evidence 71.4 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 30.1/35 · Revenue 46.8% · Profit 91.4% · Operating margin change 2 points · 88% evidence Capital efficiency 18.6/25 · ROCE 28.4% · Operating margin 24% · 100% evidence Valuation 6.2/20 · P/E 92.5× · PEG 2.31 · 65% evidence Relative strength 16.5/20 · Lead over its industry 28.1% · Lead over NIFTY 500 53.6% · 1 year 160.5% · 70% evidence · 11 of 12 weeks ahead Exact sum: 30.1 + 18.6 + 6.2 + 16.5 = 71.4 · What this means: Earnings, capital efficiency and relative strength all agree. The open questions are about management, upcoming events and risks. 2. [Kwality Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/kwality-pharmaceuticals-ltd) KPL · breaking out · Most evidence points up · 81% evidence 71.4 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 29.9/35 · Revenue 37.9% · Profit 88.4% · Operating margin change 3 points · 88% evidence Capital efficiency 18.2/25 · ROCE 24.1% · Operating margin 25% · 100% evidence Valuation 11.0/20 · P/E 44.2× · PEG 0.54 · 100% evidence Relative strength 12.3/20 · Lead over its industry n/a · Lead over NIFTY 500 74.4% · 1 year 288.9% · 25% evidence · 9 of 9 weeks ahead Exact sum: 29.9 + 18.2 + 11 + 12.3 = 71.4 · What this means: Earnings, capital efficiency and relative strength all agree. The open questions are about management, upcoming events and risks. 3. [Accent Microcell Ltd](https://www.sectoralpha.in/stocks/accent-microcell-ltd) ACCENTMIC · leader · Most evidence points up · 65% evidence 70.5 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 21.4/35 · Revenue n/a · Profit n/a · Operating margin change 7 points · 27% evidence Capital efficiency 21.4/25 · ROCE 24.9% · Operating margin 24% · 100% evidence Valuation 9.1/20 · P/E 26.9× · PEG n/a · 50% evidence Relative strength 18.6/20 · Lead over its industry 21.4% · Lead over NIFTY 500 47.6% · 1 year 132.1% · 100% evidence · 12 of 12 weeks ahead Exact sum: 21.4 + 21.4 + 9.1 + 18.6 = 70.5 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 4. [Ajanta Pharma Ltd](https://www.sectoralpha.in/stocks/ajanta-pharma-ltd) AJANTPHARM · leader · Most evidence points up · 100% evidence 69.2 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 30.3/35 · Revenue 25% · Profit 29.8% · Operating margin change 7 points · 100% evidence Capital efficiency 21.3/25 · ROCE 34.5% · Operating margin 31% · 100% evidence Valuation 7.1/20 · P/E 34.7× · PEG 1.77 · 100% evidence Relative strength 10.5/20 · Lead over its industry -3.5% · Lead over NIFTY 500 20% · 1 year 42.3% · 100% evidence · 11 of 12 weeks ahead Exact sum: 30.3 + 21.3 + 7.1 + 10.5 = 69.2 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 5. [Glenmark Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/glenmark-pharmaceuticals-ltd) GLENMARK · breaking out · Most evidence points up · 86% evidence 69.2 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 29.1/35 · Revenue 32.9% · Profit 100% · Operating margin change 2 points · 88% evidence Capital efficiency 20.3/25 · ROCE 39.8% · Operating margin 20% · 100% evidence Valuation 11.2/20 · P/E 20.8× · PEG n/a · 50% evidence Relative strength 8.6/20 · Lead over its industry -11.4% · Lead over NIFTY 500 10.8% · 1 year 21.5% · 100% evidence · 9 of 12 weeks ahead Exact sum: 29.1 + 20.3 + 11.2 + 8.6 = 69.2 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 6. [Bliss GVS Pharma Ltd](https://www.sectoralpha.in/stocks/bliss-gvs-pharma-ltd) BLISSGVS · leader · Most evidence points up · 82% evidence 67.1 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 29.3/35 · Revenue 25% · Profit 43.1% · Operating margin change 8 points · 95% evidence Capital efficiency 14.7/25 · ROCE 16.9% · Operating margin 26% · 76% evidence Valuation 6.4/20 · P/E 42.4× · PEG n/a · 50% evidence Relative strength 16.7/20 · Lead over its industry 59% · Lead over NIFTY 500 86.2% · 1 year 312.8% · 100% evidence · 12 of 12 weeks ahead Exact sum: 29.3 + 14.7 + 6.4 + 16.7 = 67.1 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 7. Fredun Pharmaceuticals Ltd this page FREDUN · breaking out · Most evidence points up · 76% evidence 65.8 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 31.9/43.75 · Revenue 50.3% · Profit 91.3% · Operating margin change 0 points · 88% evidence Capital efficiency 19.0/31.25 · ROCE 21.5% · Operating margin 14% · 100% evidence Valuation 14.9/25 · P/E 52.7× · PEG 0.77 · 100% evidence Relative strength: no reading this week · its 20 points are shared across the other three Exact sum: 31.9 + 19 + 14.9 = 65.8 (no relative-strength reading this week; its 20 points are shared across the other three) · What this means: There is no relative-strength reading for this week, so the score is built from earnings, capital efficiency and valuation alone. 8. [Lupin Ltd](https://www.sectoralpha.in/stocks/lupin-ltd) LUPIN · quiet · Most evidence points up · 89% evidence 65.4 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 27.9/35 · Revenue 28.2% · Profit 49.2% · Operating margin change 2 points · 88% evidence Capital efficiency 19.4/25 · ROCE 29.9% · Operating margin 30% · 100% evidence Valuation 16.1/20 · P/E 15.4× · PEG 0.54 · 65% evidence Relative strength 2.0/20 · Lead over its industry -24.5% · Lead over NIFTY 500 -4.7% · 1 year 2.4% · 100% evidence · 0 of 12 weeks ahead Exact sum: 27.9 + 19.4 + 16.1 + 2 = 65.4 · What this means: Earnings are strong; relative strength in its sector is -24.5% and the one-year return is 2.4%. 9. [Ipca Laboratories Ltd](https://www.sectoralpha.in/stocks/ipca-laboratories-ltd) IPCALAB · turning · Most evidence points up · 78% evidence 65.4 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 24.0/35 · Revenue 10.6% · Profit 68% · Operating margin change 6 points · 83% evidence Capital efficiency 15.7/25 · ROCE 17% · Operating margin 24% · 76% evidence Valuation 11.0/20 · P/E 35.6× · PEG n/a · 50% evidence Relative strength 14.7/20 · Lead over its industry -0.5% · Lead over NIFTY 500 23.6% · 1 year 51.7% · 100% evidence · 10 of 12 weeks ahead Exact sum: 24 + 15.7 + 11 + 14.7 = 65.4 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 10. [Marksans Pharma Ltd](https://www.sectoralpha.in/stocks/marksans-pharma-ltd) MARKSANS · leader · Evidence leans up · 74% evidence 64.1 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 28.7/35 · Revenue 19.6% · Profit 48% · Operating margin change 9 points · 88% evidence Capital efficiency 17.2/25 · ROCE 18.8% · Operating margin 25% · 100% evidence Valuation 6.3/20 · P/E 26.8× · PEG 2.85 · 65% evidence Relative strength 11.9/20 · Lead over its industry n/a · Lead over NIFTY 500 40.1% · 1 year 68.4% · 25% evidence · 12 of 12 weeks ahead Exact sum: 28.7 + 17.2 + 6.3 + 11.9 = 64.1 · What this means: Earnings, capital efficiency and relative strength all agree. The open questions are about management, upcoming events and risks. 11. [FDC Ltd](https://www.sectoralpha.in/stocks/fdc-ltd) FDC · basing · Evidence leans up · 85% evidence 62.8 out of 100 Growth Capital Valuation Relative
12. [Corona Remedies Ltd](https://www.sectoralpha.in/stocks/corona-remedies-ltd) CORONA · turning · Evidence leans up · 73% evidence 62.5 out of 100 Growth Capital Valuation Relative
13. [Emcure Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/emcure-pharmaceuticals-ltd) EMCURE · losing its lead · Evidence leans up · 71% evidence 61.8 out of 100 Growth Capital Valuation Relative
14. [Mankind Pharma Ltd](https://www.sectoralpha.in/stocks/mankind-pharma-ltd) MANKIND · turning · Evidence leans up · 100% evidence 61.0 out of 100 Growth Capital Valuation Relative
15. [Zydus Lifesciences Ltd](https://www.sectoralpha.in/stocks/zydus-lifesciences-ltd) ZYDUSLIFE · leader · Evidence leans up · 96% evidence 58.1 out of 100 Growth Capital Valuation Relative
16. [Gufic BioSciences Ltd](https://www.sectoralpha.in/stocks/gufic-biosciences-ltd) GUFICBIO · leader · Evidence leans up · 71% evidence 56.2 out of 100 Growth Capital Valuation Relative
17. [ERIS Lifesciences Ltd](https://www.sectoralpha.in/stocks/eris-lifesciences-ltd) ERIS · basing · Evidence leans up · 67% evidence 56.1 out of 100 Growth Capital Valuation Relative
18. [Strides Pharma Science Ltd](https://www.sectoralpha.in/stocks/strides-pharma-science-ltd) STAR · breaking out · Evidence leans up · 75% evidence 55.3 out of 100 Growth Capital Valuation Relative
19. [Caplin Point Laboratories Ltd](https://www.sectoralpha.in/stocks/caplin-point-laboratories-ltd) CAPLIPOINT · losing its lead · Evidence leans up · 96% evidence 54.3 out of 100 Growth Capital Valuation Relative
20. [Wockhardt Ltd](https://www.sectoralpha.in/stocks/wockhardt-ltd) WOCKPHARMA · losing its lead · Evidence leans up · 71% evidence 52.8 out of 100 Growth Capital Valuation Relative
21. [Kilitch Drugs (India) Ltd](https://www.sectoralpha.in/stocks/kilitch-drugs-indialtd) KILITCH · breaking out · Evidence leans up · 78% evidence 51.3 out of 100 Growth Capital Valuation Relative
22. [Akums Drugs & Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/akums-drugs-pharmaceuticals-ltd) AKUMS · leader · Evidence leans up · 71% evidence 50.9 out of 100 Growth Capital Valuation Relative
23. [Alkem Laboratories Ltd](https://www.sectoralpha.in/stocks/alkem-laboratories-ltd) ALKEM · quiet · Evidence leans down · 78% evidence 47.6 out of 100 Growth Capital Valuation Relative
24. [Alembic Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/alembic-pharmaceuticals-ltd) APLLTD · turning · Evidence leans down · 81% evidence 46.9 out of 100 Growth Capital Valuation Relative
25. [Bajaj Healthcare Ltd](https://www.sectoralpha.in/stocks/bajaj-healthcare-ltd) BAJAJHCARE · quiet · Evidence leans down · 100% evidence 46.5 out of 100 Growth Capital Valuation Relative
26. [Lincoln Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/lincoln-pharmaceuticals-ltd) LINCOLN · quiet · Evidence leans down · 100% evidence 46.0 out of 100 Growth Capital Valuation Relative
27. [Bharat Parenterals Ltd](https://www.sectoralpha.in/stocks/bharat-parenterals-ltd) BPLPHARMA · breaking out · Too little evidence to rank firmly · 52% evidence 45.9 out of 100 Growth Capital Valuation Relative
28. [Aurobindo Pharma Ltd](https://www.sectoralpha.in/stocks/aurobindo-pharma-ltd) AUROPHARMA · leader · Evidence leans down · 96% evidence 45.7 out of 100 Growth Capital Valuation Relative
29. [Amrutanjan Health Care Ltd](https://www.sectoralpha.in/stocks/amrutanjan-health-care-ltd) AMRUTANJAN · turning · Evidence leans down · 96% evidence 44.9 out of 100 Growth Capital Valuation Relative
30. [RPG Life Sciences Ltd](https://www.sectoralpha.in/stocks/rpg-life-sciences-ltd) RPGLIFE · losing its lead · Evidence leans down · 100% evidence 43.1 out of 100 Growth Capital Valuation Relative
31. [J B Chemicals & Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/j-b-chemicals-pharmaceuticals-ltd) JBCHEPHARM · Too little evidence to rank firmly · 59% evidence 42.6 out of 100 Growth Capital Valuation Relative
32. [Zim Laboratories Ltd](https://www.sectoralpha.in/stocks/zim-laboratories-ltd) ZIMLAB · leader · Evidence leans down · 71% evidence 42.2 out of 100 Growth Capital Valuation Relative
33. [Sun Pharmaceutical Industries Ltd](https://www.sectoralpha.in/stocks/sun-pharmaceutical-industries-ltd) SUNPHARMA · quiet · Evidence leans down · 100% evidence 39.4 out of 100 Growth Capital Valuation Relative
34. [Dr Reddys Laboratories Ltd](https://www.sectoralpha.in/stocks/dr-reddys-laboratories-ltd) DRREDDY · turning · Evidence leans down · 100% evidence 39.4 out of 100 Growth Capital Valuation Relative
35. [Natco Pharma Ltd](https://www.sectoralpha.in/stocks/natco-pharma-ltd) NATCOPHARM · quiet · Evidence leans down · 96% evidence 38.8 out of 100 Growth Capital Valuation Relative
36. [Bafna Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/bafna-pharmaceuticals-ltd) BAFNAPH · breaking out · Evidence leans down · 74% evidence 35.8 out of 100 Growth Capital Valuation Relative
37. [Cipla Ltd](https://www.sectoralpha.in/stocks/cipla-ltd) CIPLA · turning · Evidence leans down · 100% evidence 35.4 out of 100 Growth Capital Valuation Relative
38. [Torrent Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/torrent-pharmaceuticals-ltd) TORNTPHARM · losing its lead · Most evidence points down · 100% evidence 34.6 out of 100 Growth Capital Valuation Relative
39. [Biocon Ltd](https://www.sectoralpha.in/stocks/biocon-ltd) BIOCON · quiet · Most evidence points down · 96% evidence 34.4 out of 100 Growth Capital Valuation Relative
40. [Suven Life Sciences Ltd](https://www.sectoralpha.in/stocks/suven-life-sciences-ltd) SUVEN · quiet · Most evidence points down · 64% evidence 33.1 out of 100 Growth Capital Valuation Relative
41. [Influx Healthtech Ltd](https://www.sectoralpha.in/stocks/influx-healthtech-ltd) INFLUX · quiet · Too little evidence to rank firmly · 42% evidence 49.7 out of 100 Growth Capital Valuation Relative
42. [Syncom Healthcare Ltd](https://www.sectoralpha.in/stocks/syncom-healthcare-ltd) SYNCOM · Too little evidence to rank firmly · 17% evidence 42.3 out of 100 Growth Capital Valuation Relative
43. [Indoco Remedies Ltd](https://www.sectoralpha.in/stocks/indoco-remedies-ltd) INDOCO · losing its lead · Too little evidence to rank firmly · 49% evidence 38.4 out of 100 Growth Capital Valuation Relative
44. [Sai Parenterals Ltd](https://www.sectoralpha.in/stocks/sai-parenterals-ltd) SAIPARENT · turning · Too little evidence to rank firmly · 31% evidence 36.7 out of 100 Growth Capital Valuation Relative

Missing figures are not scored as bad. They lower the confidence and pull the final score toward the middle. Relative strength counts only when the company has a reading for this week; with no reading, that factor is left out and its 20 points are shared across the other three in proportion. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led NIFTY 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step path the industry is placed on (basing, turning, breaking out, leader, fading, asleep), read from how many weeks running it has led NIFTY 500 and whether that lead is growing or shrinking. It describes where the share price stands, not the direction of earnings, and it is not a recommendation; it is left blank for a company whose weekly history is too short or too stale to read. The figures in this ranking come from the industry comparison: results through the Sep 2026 quarter, and the P/E at that quarter's end. The sections above use the latest weekly price, so a P/E or return there can differ a little from the one here. The stage words in this ranking (such as losing its lead or breaking out) describe the lead over the index, not the price phase in the price section. Related companies: [Pharma - Formulators](https://www.sectoralpha.in/sectors/pharma-formulators), all 44 compared on one page. ## Which companies are close to Fredun Pharmaceuticals in size? Fredun Pharmaceuticals is the 32nd largest of 44 Pharma - Formulators companies on Sector Alpha by market value (scores of 30 October 2026). Just above it: RPG Life Sciences, Gufic BioSciences and Kwality Pharmaceuticals. Just below it: Sai Parenterals, Indoco Remedies and Accent Microcell. ### Pharma - Formulators companies close in size

1. [RPG Life Sciences Ltd](https://www.sectoralpha.in/stocks/rpg-life-sciences-ltd) ₹4,260 crore
2. [Gufic BioSciences Ltd](https://www.sectoralpha.in/stocks/gufic-biosciences-ltd) ₹4,147 crore
3. [Kwality Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/kwality-pharmaceuticals-ltd) ₹3,606 crore
4. Fredun Pharmaceuticals Ltd ₹2,341 crore
5. [Sai Parenterals Ltd](https://www.sectoralpha.in/stocks/sai-parenterals-ltd) ₹2,306 crore
6. [Indoco Remedies Ltd](https://www.sectoralpha.in/stocks/indoco-remedies-ltd) ₹1,923 crore
7. [Accent Microcell Ltd](https://www.sectoralpha.in/stocks/accent-microcell-ltd) ₹1,533 crore

[All 44 Pharma - Formulators companies, largest first](https://www.sectoralpha.in/sectors/pharma-formulators#all-companies)

### Companies close in size in other industries

1. [Amic Forging Ltd](https://www.sectoralpha.in/stocks/amic-forging-ltd) ₹2,361 crore · Castings, Forgings & Fastners
2. [Oriana Power Ltd](https://www.sectoralpha.in/stocks/oriana-power-ltd) ₹2,344 crore · Solar EPC
3. Fredun Pharmaceuticals Ltd ₹2,341 crore
4. [Utssav CZ Gold Jewels Ltd](https://www.sectoralpha.in/stocks/utssav-cz-gold-jewels-ltd) ₹2,337 crore · Diamond, Gems & Jewellery
5. [M M Forgings Ltd](https://www.sectoralpha.in/stocks/m-m-forgings-ltd) ₹2,332 crore · Castings, Forgings & Fastners

## What else do people ask about Fredun Pharmaceuticals? ### What is Fredun Pharmaceuticals's share price today? Fredun Pharmaceuticals Ltd's share price is ₹1,454.50, +183.5% over the past year. The whole company is worth ₹2,491 Cr on the market. In the last 52 weeks it traded between ₹479 to ₹1,553; today it is 91% of the way up from the low, 43.9% above its 200-day average (as of 3 November 2026). ### What were Fredun Pharmaceuticals's latest quarterly results? Fredun Pharmaceuticals Ltd reported revenue of ₹228 Cr and net profit of ₹13.0 Cr for the Jun 2026 quarter. Revenue rose 90.0% and profit rose 85.7% compared with a year earlier. Earnings per share were ₹7.98. The operating margin was 14.0%, 0.0 percentage points higher than a year earlier (as of 3 November 2026). ### What is Fredun Pharmaceuticals's market cap? Fredun Pharmaceuticals Ltd's market capitalisation is ₹2,491 Cr at a share price of ₹1,454.50. Market cap is the share price times the number of shares, so it changes whenever the price moves (as of 3 November 2026). ### How is Fredun Pharmaceuticals performing? Fredun Pharmaceuticals Ltd's share price has been rising for 70 weeks. In its latest quarter, revenue rose 90.0% and profit rose 85.7% compared with a year earlier. Over the past 13 weeks it has done better than the NIFTY 500, for 20 weeks running (as of 3 November 2026). ### Will Fredun Pharmaceuticals's share price go up? This page does not forecast Fredun Pharmaceuticals Ltd's share price. What it shows instead: the share price is ₹1,454.50, and it has been rising for 70 weeks. Its P/E of 56.1× is higher than 78% of its own last 11 years (as of 3 November 2026). ### Does Fredun Pharmaceuticals have too much debt? Fredun Pharmaceuticals Ltd has a moderate amount of debt: its debt is 0.80× its equity, and its operating profit is 2 times its interest bill. FY26 borrowings were ₹222 Cr against equity of ₹278 Cr. Keep that borrowing in mind when reading the returns on this page (as of 3 November 2026). ### Where is Fredun Pharmaceuticals in its business cycle? Fredun Pharmaceuticals Ltd's FY26 operating margin was 14.0%, against a 13-year range of 6.0% to 14.0%: the top of its range, a record year. When profit is at a record, every ratio looks better than usual, and the story depends on margins staying high. The latest quarter was 14.0%. Comparing margins with a company's own long history is a good way to see where it is in its cycle (as of 3 November 2026). ### What could break the Fredun Pharmaceuticals story? The main question: profits are rising, but only −7% of the last 3 years' profit came in as cash from operations. The gap between reported profit and actual cash is the thing to watch. On price, this page treats a rise as over when the share price closes below its 200-day average on two Fridays in a row (as of 3 November 2026). ### Is Fredun Pharmaceuticals a stock worth studying right now? What the numbers show: Fredun Pharmaceuticals Ltd's share price has risen faster than its earnings: +183.5% in a year, against +38.2% for earnings per share. The main open question: whether the cash starts to follow the profit. Every number on this page is worked out by code from the published figures, with no forecasts and no price opinions (as of 3 November 2026). ### Is there a Fredun Pharmaceuticals share price forecast for 2026? What management itself guided: New-age brands 35-45% annually and vintage business 15-20%; blended company growth 35-40% over 3 years; Fredun GX 25-35% over 5 years, or 30-35% over 4 years. ## Lists

- Momentum stocks: https://www.sectoralpha.in/momentum-stocks-india
- Pharma stocks: https://www.sectoralpha.in/sectors/pharma-stocks-india

This is research, not advice. We’re not SEBI-registered.